Breaking News Instant updates and real-time market news.

LMAT

LeMaitre

$35.92

0.36 (1.01%)

, MMSI

Merit Medical

$56.25

0.4 (0.72%)

08:36
08/07/18
08/07
08:36
08/07/18
08:36

Needham to hold a conference

3rd Annual MedTech 1:1 Conference will be held in Boston on August 7.

LMAT

LeMaitre

$35.92

0.36 (1.01%)

MMSI

Merit Medical

$56.25

0.4 (0.72%)

TTOO

T2 Biosystems

$6.09

0.74 (13.83%)

  • 07

    Aug

  • 08

    Aug

  • 14

    Aug

  • 15

    Aug

  • 13

    Sep

  • 27

    Sep

LMAT LeMaitre
$35.92

0.36 (1.01%)

06/25/18
LSCM
06/25/18
INITIATION
Target $45
LSCM
Buy
LeMaitre initiated with a Buy at Lake Street
Lake Street analyst Brooks O'Neil initiated LeMaitre Vascular with a Buy rating and $45 price target, contending that its recent biologics-focused acquisitions give it rapidly growing niche products that its sales organization can cross-sell to its installed base of vascular surgeons to expand its "already successful business."
06/08/18
06/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pfizer (PFE) and Eli Lilly (LLY) were initiated with an Overweight at Cantor Fitzgerald. 2. LivaNova (LIVN) initiated with a Buy at Stifel. 3. Occidental Petroleum (OXY) and Chevron (CVX) were initiated with a Buy at Mizuho while ConocoPhillips (COP) and Exxon Mobil (XOM) were initiated with a Neutral. 4. LeMaitre (LMAT) resumed with a Buy at Roth Capital. 5. Savara (SVRA) initiated with an Outperform, sees 300% upside, says Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/18
ROTH
06/08/18
INITIATION
Target $38
ROTH
Buy
LeMaitre resumed with a Buy at Roth Capital
Roth Capital analyst Scott Henry resumed coverage of LeMaitre Vascular with a Buy rating and $38 price target, as he expects resumed sales-force expansion to drive organic growth in the near-term and thinks the company's Reddick divestiture could help fund an acquisition, which could be a catalyst.
04/26/18
04/26/18
UPGRADE
Target $40

Buy
LeMaitre upgraded to Buy amid 'excessive' selloff at Benchmark
As previously reported, Benchmark analyst Raymond Myers upgraded LeMaitre Vascular to Buy from Hold as he believes the 20% post-earnings selloff in the shares is "excessive." He attributes the Q1 earnings shortfall mainly to sales execution issues and thinks management has already taken the necessary steps to fix the problems, he tells investors. Myers, who sees plans to expand the sales force leading to accelerating revenue growth in 2019, set a $40 price target on LeMaitre shares.
MMSI Merit Medical
$56.25

0.4 (0.72%)

07/24/18
BRRR
07/24/18
NO CHANGE
Target $61
BRRR
Outperform
Merit Medical price target raised to $61 from $50 at Barrington
Barrington analyst Michael Petusky raised his price target on Merit Medical shares to $61 from $50 after the company's Q2 revenue topped his "Street-high" estimate and the company increased its FY18 guidance, stating that Merit "clearly continues to have a lot of momentum." Management still sees gross margins improving in 2018, but not at the level previously expected, Petusky additionally noted. He maintains an Outperform rating on Merit Medical.
07/24/18
NEED
07/24/18
NO CHANGE
Target $67
NEED
Buy
Merit Medical price target raised to $67 from $54 at Needham
Needham analyst Mike Matson raised his price target on Merit Medical to $67 and kept his Buy rating after its better than expected Q2 results. The analyst notes that organic revenue growth has improved relative to Q1 despite the difficult comps and gross margins grew 60bps, even though he expected a higher rate of expansion. Matson anticipates Merit Medical to further improve in the second half of 2018 as comps ease and continued product shortage at Terumo benefits the company. The analyst also cites the positive impact from the "recent accretive acquisitions, manufacturing efficiencies, and higher margin product launches".
07/24/18
ADAM
07/24/18
NO CHANGE
Target $70
ADAM
Buy
Merit Medical price target raised to $70 from $60 at Canaccord
Canaccord analyst Jason Mils raised his price target on Merit Medical to $70 from $60 following Q2 results. The analyst noted the company delivered solid upside to expectations and he sees strong momentum in the business. He sees multiple tailwinds that could drive more upside, including increasing operating leverage, solid trends in core businesses, and supply issues at a competitor. Mills reiterated his Buy rating on Merit Medical shares.
07/24/18
PIPR
07/24/18
NO CHANGE
Target $58
PIPR
Overweight
Merit Medical transition to sizable mid-cap player continues, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says Merit Medical Systems' Q2 beat expectations and that while management lowered its full year adjusted gross margin outlook by about 100 basis points, they more importantly increased their organic revenue outlook by roughly 250 basis points at the mid-point of the range. The strength in the core business was broad-based across products and geographies, O'Brien tells investors in a research note. He notes that management anticipates benefiting from a competitor supply disruption during the remainder of the year but is taking a conservative approach to this opportunity. The analyst thinks Merit continues its transition to a sizable mid-cap player in the med tech industry. He keeps an Overweight rating on the shares with a $58 price target.
TTOO T2 Biosystems
$6.09

0.74 (13.83%)

05/30/18
HCWC
05/30/18
NO CHANGE
Target $14
HCWC
Buy
T2 Biosystems price target raised to $14 from $8.50 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for T2 Biosystems to $14 after the company announced receipt of market clearance from the FDA for the T2Bacteria panel for direct detection of bacterial species in human whole blood specimens. T2Bacteria could generate four times the volume seen with T2Candida, Selvaraju tells investors in a research note. He notes this is the first FDA-cleared test to identify sepsis-causing bacteria directly from whole blood. Importantly, T2Bacteria provides test results in approximately five hours, which is more than 2.5 days faster than blood culture-dependent tests, the analyst adds. He reiterates a Buy rating on T2 Biosystems.
06/01/18
LEER
06/01/18
UPGRADE
LEER
Outperform
T2 Biosystems upgraded to Outperform from Market Perform at Leerink
06/01/18
LEER
06/01/18
UPGRADE
Target $12
LEER
Outperform
T2 Biosystems upgraded to Outperform with $12 target at Leerink
Leerink analyst Puneet Souda upgraded T2 Biosystems to Outperform from Market Perform and raised his price target for the shares to $12 from $5. This week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B, Souda tells investors in a research note. He believes T2 is "highly underpenetrated" in its core markets, but feels it can now penetrate the broader $1.5B-$2.0B bacterial sepsis market with an immediate entry into the hospital emergency departments, which the analyst values at $300M
06/01/18
06/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying American is likely to reduce capacity starting in the post-labor day period, which should be well received by investors. 2. T2 Biosystems (TTOO) upgraded to Outperform from Market Perform at Leerink with analyst Puneet Souda saying this week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B. 3. Highwoods Properties (HIW) upgraded to Buy from Hold at Stifel with analyst John Guinee saying he believes the macro environment is changing to the positive for REITs. 4. Toyota (TM) upgraded to Outperform from Neutral at Daiwa. 5. RLJ Lodging Trust (RLJ) upgraded to Overweight from Equal Weight at Barclays with analyst Felicia Hendrix saying she views the current valuation as attractive and sees a strong RevPAR outlook for 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

HOLX

Hologic

$41.29

-0.29 (-0.70%)

16:23
11/20/18
11/20
16:23
11/20/18
16:23
Hot Stocks
Hologic VP Allison Bebo sells 6,500 shares of company stock »

Hologic VP Allison Bebo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 30

    Nov

CAL

Caleres

$30.93

-1.165 (-3.63%)

16:23
11/20/18
11/20
16:23
11/20/18
16:23
Earnings
Caleres lowers FY18 adj. EPS view to $2.25-$2.35 from $2.40-$2.50 »

Consensus $2.46. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

K

Kellogg

$61.72

0.03 (0.05%)

16:22
11/20/18
11/20
16:22
11/20/18
16:22
Hot Stocks
Kellogg CFO acquires 8,190 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

FLR

Fluor

$41.39

-2.26 (-5.18%)

16:20
11/20/18
11/20
16:20
11/20/18
16:20
Hot Stocks
Fluor selected for lithium, boron mine project in Nevada »

Fluor Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

TGT

Target

$69.05

-8.08 (-10.48%)

, BBY

Best Buy

$63.54

1.35 (2.17%)

16:20
11/20/18
11/20
16:20
11/20/18
16:20
OnTheFly
Fly Intel: Wall Street's top stories for Tuesday »

Stocks began the session…

TGT

Target

$69.05

-8.08 (-10.48%)

BBY

Best Buy

$63.54

1.35 (2.17%)

CPB

Campbell Soup

$40.57

2.1 (5.46%)

KLIC

Kulicke & Soffa

$21.25

1.345 (6.76%)

A

Agilent

$67.61

5.04 (8.06%)

LIVN

LivaNova

$98.00

-22.28 (-18.52%)

LB

L Brands

$28.43

-6.105 (-17.68%)

AAPL

Apple

$177.10

-8.7 (-4.68%)

BSX

Boston Scientific

$34.05

-1.24 (-3.51%)

NAVI

Navient

$10.74

-1.255 (-10.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 27

    Nov

  • 29

    Nov

  • 04

    Dec

  • 05

    Dec

  • 11

    Dec

  • 03

    Mar

USAT

USA Technologies

$4.96

-0.055 (-1.10%)

16:20
11/20/18
11/20
16:20
11/20/18
16:20
Hot Stocks
USA Technologies provides update on Nasdaq notification of deficiency »

USA Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
11/20/18
11/20
16:20
11/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for November 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMK

GenMark

$5.01

(0.00%)

16:19
11/20/18
11/20
16:19
11/20/18
16:19
Syndicate
Breaking Syndicate news story on GenMark »

GenMark files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

CAL

Caleres

$30.93

-1.165 (-3.63%)

16:18
11/20/18
11/20
16:18
11/20/18
16:18
Earnings
Caleres reports Q3 adj. EPS 81c, consensus 88c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

RMBL

RumbleON

$5.76

-0.35 (-5.73%)

16:18
11/20/18
11/20
16:18
11/20/18
16:18
Syndicate
Breaking Syndicate news story on RumbleON »

RumbleON files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 10

    Dec

GPS

Gap

$24.65

-0.79 (-3.11%)

16:18
11/20/18
11/20
16:18
11/20/18
16:18
Earnings
Gap narrows FY18 EPS view to $2.55-$2.60 from $2.55-$2.70, consensus $2.56 »

Backs FY18 SSS view of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

MRCY

Mercury Systems

$46.80

-0.48 (-1.02%)

16:18
11/20/18
11/20
16:18
11/20/18
16:18
Hot Stocks
Mercury Systems gets $6.7M Integrated subsystems order for naval electronics »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRI

Thomson Reuters

$47.83

-0.59 (-1.22%)

16:17
11/20/18
11/20
16:17
11/20/18
16:17
Hot Stocks
Thomson Reuters receives court approval for return of capital transaction »

Thomson Reuters announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

STRM

Streamline Health

$0.90

(0.00%)

, WFC

Wells Fargo

$52.54

-0.77 (-1.44%)

16:17
11/20/18
11/20
16:17
11/20/18
16:17
Hot Stocks
Streamline Health extends banking agreement with Wells Fargo into 2020 »

Streamline Health…

STRM

Streamline Health

$0.90

(0.00%)

WFC

Wells Fargo

$52.54

-0.77 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
11/20/18
11/20
16:17
11/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$24.65

-0.79 (-3.11%)

16:16
11/20/18
11/20
16:16
11/20/18
16:16
Earnings
Gap reports Q3 EPS 69c, consensus 68c »

Reports Q3 revenue $4.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
11/20/18
11/20
16:16
11/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.10

-2.69 (-5.51%)

16:14
11/20/18
11/20
16:14
11/20/18
16:14
Hot Stocks
Breaking Hot Stocks news story on Foot Locker »

Foot Locker up 11% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BJ

BJ's Wholesale

$19.85

-0.22 (-1.10%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Hot Stocks
Breaking Hot Stocks news story on BJ's Wholesale »

BJ's Wholesale now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

FL

Foot Locker

$46.05

-2.74 (-5.62%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Hot Stocks
Foot Locker CFO says 'encouraged' by Q3 SSS growth »

"We're…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

HTBX

Heat Biologics

$2.04

0.14 (7.37%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Syndicate
Heat Biologics fiels to sell common stock and warrants, no amount given »

A.G.P./Alliance Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$46.14

-2.65 (-5.43%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Hot Stocks
Foot Locker reports merchandise inventories $1.305B at November 3 »

As of November 3, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TWI

Titan International

$6.51

-0.4 (-5.79%)

16:13
11/20/18
11/20
16:13
11/20/18
16:13
Hot Stocks
Titan International receives settlement put option notice »

Titan International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$33.93

-0.69 (-1.99%)

16:12
11/20/18
11/20
16:12
11/20/18
16:12
Hot Stocks
Mylan announces voluntary recall of select lots of Valsartan-containing products »

Mylan announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

BJ

BJ's Wholesale

$19.83

-0.24 (-1.20%)

16:12
11/20/18
11/20
16:12
11/20/18
16:12
Earnings
BJ's Wholesale raises FY18 adj. EPS view to $1.22-$1.26 from $1.17-$1.24 »

Consensus $1.23. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.